<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2159">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200911</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20190850H</org_study_id>
    <nct_id>NCT04200911</nct_id>
  </id_info>
  <brief_title>Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway</brief_title>
  <acronym>(CARPE DIEM)</acronym>
  <official_title>Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway (CARPE DIEM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in&#xD;
      older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and&#xD;
      investigate associated safety, tolerability, target engagement, cognition, and functional&#xD;
      status as initial proof-of-concept study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label pilot study of orally administered RAPA to measure its target&#xD;
      engagement in Cerebrospinal Fluid (CSF) and blood, and to establish the feasibility and&#xD;
      safety of RAPA treatment in older adults with MCI and early stage AD as initial&#xD;
      proof-of-concept for a larger Phase 2 clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Actual">January 13, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood brain barrier penetration of RAPA</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>Lumbar punctures will be performed at baseline and after the final RAPA dose, to assess CSF levels of the drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Number of adverse events experienced</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target engagement of RAPA treatment in Alzheimer's Disease (AD)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Evaluation of relevant AD biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Exam (MMSE)</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>A 30 point questionnaire used to measure cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale (ADAS-Cog) Word list Immediate and Delayed</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>A scale used to assess progression of Alzheimer's Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electronic Gait Mapping</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>Assessment of physical functioning under single and dual task conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>Assessment of physical function using grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating (CDR)</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>A 5 point scale used to characcterize six domains of cognitive an functional performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benson Figure Copy</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>A scale used to test memory recall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tablet-Based Cognitive Assessment (TabCat)</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>A scale used to score cognitive assessment based on a number of assigned tasks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Deterioration Scale</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>A caregiver assessment of the stage of AD progression from Stage 1-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>A scale to assess dementia-related behavioral symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional activities questionnaire (FAQ)</measure>
    <time_frame>Change from Baseline to 8 weeks</time_frame>
    <description>An informant rates the subject's ability using a scoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Change from baseline to 8 weeks</time_frame>
    <description>A questionnaire used to assess sleep quality</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cognitive Impairment, Mild</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>RAPA intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus 1mg orally once a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamune</intervention_name>
    <description>Sirolimus 1mg capsules</description>
    <arm_group_label>RAPA intervention</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Mild Cognitive Impairment (MCI), Clinical Dementia Rating Scale&#xD;
             (CDR)=0.5-1; Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall ≤5% based on&#xD;
             age-adjusted normal values, clinician approved&#xD;
&#xD;
          -  Normal blood cell counts without clinically significant excursions&#xD;
&#xD;
          -  A Legally Authorized Representative (LAR) if necessary for consent&#xD;
&#xD;
          -  An LAR or study partner to accompany participant to all visits&#xD;
&#xD;
          -  Availability for all study visits&#xD;
&#xD;
          -  Stable dose of AD medications) Donepezil, rivastigmine, memantine, galantamine) for at&#xD;
             least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes (HbA1c≥6.5% or anti-diabetic medications)&#xD;
&#xD;
          -  History of skin ulcers or poor wound healing&#xD;
&#xD;
          -  Current tobacco or illicit drug use or alcohol abuse&#xD;
&#xD;
          -  Use of anti-platelet or anti-coagulant medications other than aspirin&#xD;
&#xD;
          -  Current medications that affect cytochrome P450 3A4&#xD;
&#xD;
          -  Immunosuppressant therapy within the last year&#xD;
&#xD;
          -  Chemotherapy or radiation treatment within the last year&#xD;
&#xD;
          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities&#xD;
&#xD;
          -  Current or chronic history of pulmonary disease or abnormal pulse oximetry (&lt;90%)&#xD;
&#xD;
          -  Chronic heart failure&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Recent history (past 6 months) of myocardial infarction, active coronary artery&#xD;
             disease, intestinal disorders, stroke, or transient ischemic attack&#xD;
&#xD;
          -  significant neurological conditions other than AD&#xD;
&#xD;
          -  Poorly controlled blood pressure (systolic BP&gt;160, diastolic BP&gt;90mmHg)&#xD;
&#xD;
          -  Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant,&#xD;
             and/or psychiatric disease&#xD;
&#xD;
          -  History of, or Magnetic Resonance Imaging (MRI) positive for any space occupying&#xD;
             lesion, including mass effect and/or abnormal intracranial pressure, which would&#xD;
             indicate contraindication to lumbar puncture&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitzi Gonzales, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UTHSA McDermott Clinical Sciences Building</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>February 3, 2022</last_update_submitted>
  <last_update_submitted_qc>February 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

